Skip to main content

Medical Professional Hub

Article updates

View the latest article updates on Patient.

Sepsis

What is sepsis? Sepsis is defined as life-threatening organ dysfunction due to a dysregulated host response to infection. Septic shock is associated with particularly profound circulatory, cellular and metabolic abnormalities, with a greater risk of mortality than with sepsis alone. Sepsis is defined as life-threatening organ dysfunction due to a dysregulated host response to infection. Septic shock describes circulatory, cellular, and metabolic abnormalities which are associated with a greater risk of mortality than sepsis alone. Patients with septic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L in the absence of hypovolaemia. This combination is associated with hospital mortality rates greater than 40%. The Surviving Sepsis Campaign (SSC) was established to raise awareness of severe sepsis and to improve its management. The SSC is a collaboration between several groups worldwide and its aim is to reduce the mortality from sepsis. Pathophysiology of sepsis The exact pathophysiology of sepsis is unknown, but it is thought to be a multifactorial response to an infecting pathogen that may be amplified by host factors (eg, genetics, age, and co-morbidities), the pathogen (type, virulence, and burden), and the environment. test start--- test test end--- The exact mechanism of cell injury is not fully known, but it is suspected that immune and coagulation systems are switched on by infection and cause dysfunction of one or more organs with variable severity. It is thought this involves the early activation of both pro-inflammatory responses (leading to cellular and tissue damage) and anti-inflammatory responses (leading to immunosuppression). Resulting tissue hypoxia, mitochondrial dysfunction, macrovascular and microvascular dysfunction, and cell death are thought to be mediators of organ dysfunction. The most common sites of infection leading to sepsis are the respiratory, gastrointestinal, renal and genitourinary tracts, as well as blood, skin, soft tissue, bone and joint sources. Studies indicate an equal prevalence of Gram-positive and Gram-negative bacterial infections in sepsis, particularly Staphylococcus aureus, Pseudomonas species, and Escherichia coli. In children, Neisseria meningitides and Haemophilus influenzae may also be involved. Rarely, fungal, viral, or parasitic infections are the cause. No causative pathogen is identified in about one-third of people with sepsis. How common is sepsis? (Epidemiology) Sepsis is a leading cause of morbidity and mortality for children worldwide. Globally, an estimated 22 cases of childhood sepsis per 100,000 person-years and 2,202 cases of neonatal sepsis per 100,000 live births occur, translating into 1.2 million cases of childhood sepsis per year. The most recent global estimates for sepsis incidence and mortality were based on data for adults admitted to hospital in seven high-income countries and reported 19.4 million sepsis incident cases and 5.3 million sepsis-related deaths annually. As only high-income countries are represented this may be a significant underestimate. However, it has been deduced that more than 1 in 1,000 people in developed countries develop sepsis each year and between a third and a half of them progress to severe sepsis. The figures for developing countries are likely to be far higher. Risk factors There is usually an abscess or nidus of infection, which may be occult. Risk factors for developing sepsis include the following: The very young (under 1 year) and older people (over 75 years), or people who are very frail. People who have impaired immune systems because of illness or drugs, including: People having treatment for cancer with chemotherapy. People who have impaired immune function (eg, people with diabetes, people who have had a splenectomy, or people with sickle cell disease. People taking long-term steroids. People taking immunosuppressant drugs to treat non-malignant disorders such as rheumatoid arthritis. People who have had surgery, or other invasive procedures, in the past 6 weeks. People with any breach of skin integrity (eg, cuts, burns, blisters or skin infections. People who misuse drugs intravenously. People with indwelling lines or catheters. People who are pregnant, have given birth or had a termination of pregnancy or miscarriage in the past 6 weeks. Risk factors for early-onset neonatal infection: Suspected or confirmed infection in another baby in the case of a multiple pregnancy. Invasive group B streptococcal infection in a previous baby or maternal group B streptococcal colonisation, bacteriuria or infection in the current pregnancy. Pre-term birth following spontaneous labour before 37 weeks' gestation. Confirmed rupture of membranes for more than 18 hours before a pre-term birth. Confirmed prelabour rupture of membranes at term for more than 24 hours before the onset of labour. Intrapartum fever higher than 38°C if there is suspected or confirmed bacterial infection. Chorioamnionitis. Symptoms of sepsis (presentation) Patients may have presented a few days earlier with a focus of infection. Patients may then deteriorate rapidly despite having the appropriate oral antibiotics. People with sepsis may have non-specific, non-localised presentations, eg, feeling very unwell, and may not have a high temperature. There may be concerns expressed by the person and their family or carers, eg, changes from usual behaviour. Also enquire about symptoms relating to a possible focus of infection - eg, cough, urinary symptoms, recent travel. Ask about frequency of micturition in the past 18 hours. Presenting features for children may include feeling abnormally cold to touch, looking mottled and blue or with very pale skin, a rash that does not fade with pressure, raised respiratory rate and being very lethargic and difficult to wake up. Young children may not feed, may have repeated vomiting or may not pass any urine and so not have wet nappies. Assessment A high degree of vigilance is required for early identification of a patient with sepsis in primary care. Evaluate risk level using the person's history, physical examination results and criteria based on age. The NICE guideline includes stratification of risk from sepsis in under 5s, children aged 5 to 11, children and young people aged 12 to 15, and for those aged 16 years and older. Assess people with any suspected infection to identify: Possible source of infection. Factors that increase risk of sepsis. Any indications of clinical concern, such as new-onset abnormalities of behaviour, circulation or respiration. Use a structured set of observations to assess people in a face-to-face setting to stratify risk if sepsis is suspected. Ask how often the person urinated in the past 18 hours, any recent fever or rigors, and whether they have recently presented with symptoms or signs that could indicate sepsis. Use the national early warning score (NEWS2) - see 'Sepsis screening' below - to assess people with suspected sepsis who are aged 16 or over, are not and have not recently been pregnant, and are in an acute hospital setting, acute mental health setting or ambulance. Consider using an early warning score to assess people with suspected sepsis who are: Aged under 16, in any setting. Pregnant or have recently been pregnant, in any setting. Aged 16 or over, in a community or custodial setting. Suspect neutropenic sepsis in people who become unwell and: Are having or have had systemic anticancer treatment within the last 30 days. Are receiving or have received immunosuppressant treatment for reasons unrelated to cancer. Use clinical judgement to determine whether any past treatment may still be likely to cause neutropenia. Refer patients with suspected neutropenic sepsis immediately for assessment in secondary or tertiary care. Initial examination Assess temperature, heart rate, respiratory rate, blood pressure, level of consciousness, oxygen saturation and capillary refill time. In community settings, measure oxygen saturation if equipment is available and taking a measurement does not cause a delay in assessment or treatment. Examine people with suspected sepsis for (see also Meningococcal Disease): Mottled or ashen appearance. Cyanosis of the skin, lips or tongue. Non-blanching petechial or purpuric rash. Any breach of skin integrity (eg, cuts, burns or skin infections). Other rash indicating potential infection. As part of the initial assessment, carry out a thorough clinical examination to look for sources of infection, including sources that might need drainage or other interventions. Sepsis screening The National Early Warning Score (NEWS) is a tool developed by the Royal College of Physicians which improves the detection and response to clinical deterioration in adult patients and is a key element of patient safety and improving patient outcomes. The National Early Warning System (NEWS) was introduced by the Royal College of Physicians in 2012. In December 2017, an updated version of NEWS, NEWS2, was published. See the reference link for further information. The National Early Warning System (NEWS2) is based on a simple scoring system in which a score is allocated to physiological measurements already undertaken when patients present to, or are being monitored in, hospital. NEWS is more accurate in predicting 10- and 30-day mortality than other systems when patients present to A&E with suspected sepsis. Six simple physiological parameters form the basis of the scoring system: 1. Respiratory rate 2. Oxygen saturations 3. Temperature 4. Systolic blood pressure 5. Pulse rate 6. Level of consciousness A score is allocated to each as they are measured, the magnitude of the score reflecting how extremely the parameter varies from the norm. The score is then aggregated. Evidence suggests using the system is associated with improved patient outcomes. Management of sepsis The following is a brief summary of the NICE guidance. See the reference link to the NICE guideline for further information. Managing suspected sepsis outside acute hospital settings Refer people with suspected sepsis for emergency medical care if: They meet any high risk criteria, or Their immunity is impaired by drugs or illness and they meet any moderate to high risk criteria. Use the most appropriate means of transport (usually 999 ambulance). Pre-alert secondary care (through GP or ambulance service) when any high risk criteria are met in a person under 16 with suspected sepsis outside of an acute hospital, and transfer them immediately. Managing the condition while awaiting transfer In remote and rural locations where transfer time to emergency department is routinely more than 1 hour, ensure GPs have mechanisms in place to give antibiotics to people with high risk criteria in pre-hospital settings. If immediate transfer to hospital is not required Assess people who are outside acute hospital settings with suspected sepsis and any moderate to high risk criteria to: Make a definitive diagnosis of their condition. Decide whether their condition can be treated safely outside hospital. If a definitive diagnosis is not reached or the person's condition cannot be treated safely outside an acute hospital setting, refer them urgently for emergency care. Managing suspected sepsis in acute hospital settings Initial investigations to find the source of infection Start looking for the source of infection and take microbiological and blood samples before giving an antimicrobial. Initial blood tests should include blood gas, including glucose and lactate measurement, blood culture, full blood count, C-reactive protein, renal function and electrolytes, liver function tests and clotting screen. Give a broad-spectrum antimicrobial at the maximum recommended dose, without delay (within 1 hour of identifying that they meet any high risk criteria), if antibiotics have not already been given for this episode of sepsis. When the source of infection is confirmed or microbiological results are available: review the choice of antibiotic(s) and change the antibiotic(s) according to results, using a narrower-spectrum antibiotic, if appropriate. Give intravenous fluid bolus without delay (within 1 hour of identifying that they meet any high risk criteria). Refer to a critical care specialist or team for them to review, including their need for central venous access and initiation of inotropes or vasopressors. See the NICE guideline reference link for further information. Prognosis Organ dysfunction is an important predictor of prognosis, with multiple organ involvement being associated with a higher risk of mortality. Extremes of age and the presence of co-morbidities are also associated with a worse prognosis. A UK Sepsis Trust report cites an overall mortality rate in England of 28.9%. A UK observational cohort study of 91 intensive care units (n = 56,673) found that the hospital mortality rate of adults admitted with sepsis ranged from 17% in people aged 16–19 years, to 64% in people aged over 85 years. A diagnosis of septic shock is associated with hospital mortality rates greater than 40%. An international study of the association between following Surviving Sepsis Campaign (SSC) performance criteria and mortality rate found the overall hospital mortality for people with sepsis and septic shock was 32.8%. The case fatality rate of sepsis may be falling over time, presumably due to increased awareness and reporting of suspected sepsis, faster diagnosis, and improved management protocols. Survivors of sepsis have higher rates of mortality following hospital discharge compared with control populations. Compared to non-sepsis admissions, sepsis survivors have a greater risk of re-admission, with 30-day re-admission rates averaging between 19–32%. People who survive sepsis may have long-term physical, psychological, and cognitive impairments. Complications of sepsis Death (see 'Prognosis' section above). Organ failure: this may be multi-system and includes acute kidney injury, cholestasis, heart failure, acute respiratory distress syndrome (ARDS) or acute lung injury, and bone marrow suppression. Recurrent and secondary infection. Malnutrition. Coagulopathy: this may cause thromboembolism or disseminated intravascular coagulation (DIC) characterised by microthrombosis and haemorrhage. Physical impairments: a reduced quality of life may result from chronic pain and fatigue. Encephalopathy and delirium may lead to reduced mobility and neuromuscular weakness, as well as longer lasting neurocognitive deficits such as memory problems and reduced concentration. Psychological sequelae may include anxiety about recurrent infection and sepsis, post-traumatic stress disorder, loss of confidence and self-esteem. Post-sepsis syndrome Post-sepsis syndrome (PSS) is associated with several pathophysiologic mechanisms that negatively affect quality of life, long-term health and lifespan. These pathophysiologic mechanisms include immune dysregulation, persistent inflammation, oxidative stress and mitochondrial dysfunction. PSS can manifest in various ways including: Physical difficulties include fatigue, weakness, breathlessness, chest pains, oedema, arthralgia, poor appetite, visual disturbance, sensory disturbance and recurrent infections. Psychological difficulties may include anxiety, depression, post-traumatic stress disorder, nightmares, insomnia, poor concentration and memory disturbance. Original document (2016) produced in collaboration with Dr Ron Daniels of The UK Sepsis Trust.

21 Feb 2024

Important complications of anaesthesia

Anaesthesia Anaesthesia is from the Greek and means 'loss of sensation'. Anaesthesia allows invasive and painful procedures to be performed with little distress to the patient. There are three main types of anaesthesia. General anaesthesia The patient is sedated, using either intravenous medications or gaseous substances, and occasionally muscles paralysed, requiring control of breathing by mechanical ventilation. Regional anaesthesia This can be described as central where anaesthetic drugs are administered directly in or around the spinal cord, blocking the nerves of the spinal cord (eg, epidural or spinal anaesthesia). The main benefit of this method is that ventilation is not needed (provided the block is not too high). Regional anaesthesia can also be peripheral - for example: Plexus blocks - eg, brachial plexus. Nerve blocks - eg, femoral. Intravenous blocks whilst preventing venous flow out of the region - eg, Bier's block. Local anaesthesia In this method the anaesthetic is applied to one site, usually topically or subcutaneously. Important complications of general anaesthesia The practice of anaesthesia is fundamental to the practice of medicine. However, anaesthesia is not without its problems. It is difficult to determine exactly the incidence of deaths directly attributable to general anaesthetics, as the cause of death is often multifactorial and study methodology varies making comparisons difficult. In 1987 a confidential enquiry into perioperative deaths revealed that very few deaths were actually as a direct result of general anaesthesia - there was an incidence of 1 in 185,086 (first Confidential Enquiry into Perioperative Deaths (CEPOD)). More recently in a Swiss single tertiary centre data analysis between 2003 and 2019, 1.5 deaths occurred for every 100,000 patients. Figures of anaesthetic-related morbidity are more difficult to determine. Although general anaesthesia is not without risk, it should be remembered that it allows necessary procedures to be performed in a humane way - without which the patient might otherwise die. Along these lines, if a patient is high-risk for a general anaesthetic (eg, pre-existing comorbidities) then they should still be referred for surgery like any other patient. The decision to operate and which form of anaesthesia to use should then be decisions made by the surgeon and anaesthetist. Important complications of general anaesthesia Important information Pain. Nausea and vomiting - up to 30% of patients. Damage to teeth. Sore throat and laryngeal damage. Anaphylaxis to anaesthetic agents - approximately 1 in 3,000. Cardiovascular collapse. Respiratory depression. Aspiration pneumonitis - non-obstetric emergency rate between 1 in 373 to 1 in 895. Hypothermia. Hypoxic brain damage. Nerve injury. Awareness during anaesthesia. Embolism - air, thrombus, venous or arterial. Backache. Headache. Idiosyncratic reactions related to specific agents - eg, malignant hyperpyrexia with suxamethonium, succinylcholine-related apnoea. Iatrogenic - eg, pneumothorax related to central line insertion. Death. Some specific complications of general anaesthesia Anaphylaxis Anaphylaxis can occur to any anaesthetic agent and in all types of anaesthesia. The severity of the reaction may vary but features may include rash, urticaria, bronchospasm, hypotension, angio-oedema, and vomiting. It needs to be carefully looked for in the pre-operative assessment and previous general anaesthetic charts may help. Patients who are suspected of an allergic reaction should be referred for further investigation to try to determine the exact cause. If necessary, this may involve provocation testing or skin prick testing and patients should be referred to local immunologists. Anaphylaxis needs to be promptly recognised and managed and patients should be advised to wear a medical emergency identification bracelet or similar once they recover. Aspiration pneumonitis A reduced level of consciousness can lead to an unprotected airway. If the patient vomits they can aspirate the vomitus contents into their lungs. This can set up lung inflammation with infection. The risk of aspiration pneumonitis and aspiration pneumonia is reduced by fasting for several hours prior to the procedure and cricoid cartilage pressure during induction of anaesthesia. However, the evidence for the use of cricoid pressure is not clearly documented and further investigation is required. Other methods of reducing aspiration pneumonitis associated with anaesthesia are the use of metoclopramide to enhance gastric emptying or proton pump inhibitors to increase the pH of gastric contents. Aspiration pneumonitis may also occur in spinal anaesthesia if the level of spinal block is too high, leading to paralysis or impairment of the vocal cords and respiratory impairment. Peripheral nerve damage This can occur with all the types of anaesthesia and results from nerve compression. The most common cause is exaggerated positioning for prolonged periods of time. Both the anaesthetist and the surgeons should be aware of this potential complication and patients should be moved on a regular basis if possible. The severity varies and recovery may be prolonged. The most common nerves affected are the ulnar nerve and the common peroneal nerve. More rarely, the brachial plexus may be affected. Injury to nerves can be avoided by prevention of extreme postures for lengthy periods during surgery. If nerve damage occurs then patients should be followed up and further investigations such as electromyography may be required. Damage to teeth It is now common practice to check the teeth in the anaesthetist's pre-operative assessment. Damage to teeth is actually the most common cause of claims made against anaesthetists. In a 2023 systematic review and meta-analysis, during the peri-operative period, the majority of dental injuries (50–75%) occur during tracheal intubation. The overall incidence of dental injury is estimated to be between 0.06% and 12%, but these values may be underestimated. The tooth most commonly affected is the upper left incisor. Embolism Embolism is rare during an anaesthetic but is potentially fatal. Air embolism occurs more commonly during neurosurgical procedures or pelvic operations. Prophylaxis of thromboembolism is common and begins pre-operatively with thromboembolic deterrents (TEDS) and low molecular weight heparin (LMWH). Important complications of regional anaesthesia Central regional anaesthesia was first used at the end of the 18th century. It provided a method of blocking afferent and efferent nerves by injecting anaesthetic agents in either the epidural space around the spinal cord (epidural anaesthesia) or directly in the cerebrospinal fluid surrounding the spinal cord (ie in the subarachnoid space called spinal anaesthesia). All nerves are blocked including motor nerves, sensory nerves and nerves of the autonomic system. Epidural anaesthesia takes slightly longer than spinal anaesthesia to take effect and provides predominantly analgesic properties. With both, the need for muscle paralysis and ventilation is not usually required but there is a risk that a high block will impair respiration, meaning that ventilation will be necessary. A 2017 Cochrane systematic review showed that regional anaesthesia is associated with reduced mortality and reduction in serious complications in comparison with general anaesthesia. However, a 2022 systematic review and meta-analysis of RCTs comparing outcomes in those having general anaesthetic or spinal anaesthetic showed that spinal anaesthesia reduced the risk of acute kidney injury compared with GA: RR=0.59 (95% CI, 0.39-0.89), but there were no significant differences in the risk of other outcomes. Important complications of regional anaesthesia Important information Pain - patients may still experience pain despite spinal anaesthesia. Post-dural headache from cerebrospinal fluid (CSF) leak. Hypotension and bradycardia through blockade of the sympathetic nervous system. Limb damage from sensory and motor block. Epidural or intrathecal bleed. Respiratory failure if block is 'too high'. Direct nerve damage. Hypothermia. Damage to the spinal cord - may be transient or permanent. Spinal infection. Aseptic meningitis. Haematoma of the spinal cord - enhanced by use of LMWH pre-operatively. Anaphylaxis. Urinary retention. Spinal cord infarction. Anaesthetic intoxication. Some specific complications of regional anaesthesia Post-dural puncture headache Post-dural puncture headache is very common after spinal anaesthesia and especially in young adults and obstetrics. Unintentional dural puncture occurs in 0.15-1.5% of labour epidural analgesia and 50-80% of these women develop post-dural puncture headache. The headache results from CSF leak from the puncture site. It is increased by use of larger-gauge needles and reduced by atraumatic needles. Presenting symptoms may include headache, photophobia, vomiting and dizziness. Post-dural puncture headache is usually treated with analgesia, bed rest and adequate hydration. Occasionally epidural blood patch is used where 15 ml of the patient's blood are injected at the site of the meningeal tear. Caffeine is also used and acts as a stimulant of the CNS and has shown benefit. Other medications with benefit include gabapentin, theophylline and hydrocortisone. Total spinal block Total spinal block can occur with the injection of large amounts of anaesthetic agents into the spinal cord. It is detected by a high sensory level and rapid muscle paralysis. The block moves up the spinal cord so that respiratory embarrassment may occur, as can unconsciousness. In these situations the patient needs prompt assessment and may need to be intubated and ventilated until the spinal block wears off. The quoted incidences vary between 1 in 2,971 and 1 in 16,200 anaesthetics. Hypotension Hypotension during spinal anaesthesia for elective caesarean delivery occurs in as many as 70% to 80% of women receiving pharmacological prophylaxis. They develop transient hypotension as sympathetic nerves are blocked. This usually responds to prompt fluid replacement, usually starting with crystalloids followed by colloids. Occasionally hypotension can be severe and may require vasopressors along with fluids. Care must be taken in patients with a cardiac history, as they may develop myocardial ischaemia with minor drops in blood pressure. It is suggested that heart rate variability prior to spinal anaesthesia represents autonomic dysfunction and may help determine patients who are more likely to develop hypotension. Cases of bradycardia with asystole leading to cardiac arrest have also occurred and it appears the underlying aetiology is complicated and not just related to autonomic dysfunction. Neurological deficits Cauda equina syndrome may occur and can be transient or permanent. This is a common reason for patients to refuse spinal anaesthesia. There may also be traumatic injury to the spinal cord. Adhesive arachnoiditis is a longer-term sequela of spinal anaesthesia, occurring weeks and even months later. It is characterised by proliferation of the meninges and vasoconstriction of spinal cord blood vessels. This results in gradual sensory and motor deficits from ischaemia and infarction of the spinal cord. Important complications of local anaesthesia All forms of anaesthetics are invasive to a patient and therefore consent should be obtained as for other procedures. Ideally patients should be given a leaflet regarding anaesthesia and then counselled regarding the intended benefits and the risks of anaesthesia. In a general practice setting it will be the responsibility of the clinician who administers the local anaesthesia to ensure fully informed, non-coercive consent is obtained.

14 Feb 2024

Adult asthma

Current British Guidelines on the Management of Asthma provide the following recommendations for the management of asthma. General principles of adult asthma management Step up/down treatment according to disease severity to maintain good control and minimise drug-related side-effects. Start at the step most fitting to the initial severity of the asthma. Treatment plans and goals should be negotiated with the patient but usual aims would be to minimise impact of adult asthma symptoms on life, reduce reliance on reliever medication and prevent severe exacerbations. Self-management education including individualised written asthma action plans should be offered. Always check concordance with medication/existing action plan, effective inhaler technique and the presence/absence of trigger factors before initiating new drug therapy. It is very important to consider the upper respiratory tract when treating asthma. It is much more difficult to treat asthma successfully if co-existing allergic rhinitis is not adequately controlled. See also the separate Occupational Asthma, Asthma (bronchial) and Acute Severe Asthma and Status Asthmaticus articles. Asthma reviews Routine asthma care is largely carried out in primary care. Practices must keep a register of patients with asthma to ensure adequate follow-up and audit. All patients with asthma should be reviewed at least annually, more often if disease is less well controlled or recently diagnosed. Reviews should be carried out by a nurse or doctor with appropriate and up-to-date training and should include: Current symptoms using objective measures: Alternatives include the Asthma Control Questionnaire, Asthma Control Test and Mini Asthma Quality of Life Questionnaire. Record an up-to-date smoking status; offer smoking cessation advice and support where appropriate. Record any acute exacerbations since last seen. Check medication use - a prescription count can indicate overuse/underuse of medication, inhaler and spacer, problems and side-effects. The use of more than two canisters of short-acting beta2 agonist per month - or 10-12 puffs per day - is associated with poorly controlled and higher-risk asthma. Check immunisation (pneumococcal/influenza) status. Review peak flow diaries and record current peak expiratory flow rate (PEFR)/spirometry values. Address any educational needs. Provide/update a written action plan. Consider home monitoring of PEFR - useful particularly in those with severe or brittle asthma and those who have difficulty recognising symptom deterioration. Agree duration of subsequent follow-up and ensure the patient is aware of how to seek help if their asthma deteriorates. Asthma action plans All patients with asthma should have an individually tailored action plan to include: What medication they are on and how it works. How to titrate their medication in times of exacerbation and when to seek help. How to manage severe asthma symptoms. When to contact emergency services. The National Institute for Health and Care Excellence (NICE) has also advised that approaches to reducing air pollution (both indoors and outdoors) should be part of this plan, as pollution can trigger and exacerbate asthma. These should include: Approaches to minimising indoor air pollution and reducing exposure to outdoor air pollution should be included in a personalised action plan because pollution can trigger and exacerbate asthma. Advising patient about indoor air pollutants - including nitrogen dioxide, damp, mould, particulate matter and volatile organic compounds (VOCs). If mould or other indoor pollutants could be exacerbating a patient's symptoms, they should be helped to request a housing assessment from the local authority. Avoiding household sprays, air fresheners or aerosols and using non-spray alternatives, if patients' sympoms are triggered by these. The use of remote technology such as telephone reviews, SMS and the internet has received mixed response from patients and healthcare professionals alike. However, the British guideline on asthma still acknowledges telephone contact as being effective in providing ongoing support and advice. Non-drug treatment for adult asthma All people with asthma (and/or their carers) should be offered self-management education (including a written personalised asthma action plan as discussed above) and be supported by regular professional reviews. Self-management could include: Smoking cessation. Smoking exacerbates asthma symptoms. It increases the risk of persistent asthma in teenagers who smoke. Clear personalised advice should be given to stop smoking and help provided with nicotine replacement therapy, etc, where appropriate. Weight reduction in obese patients improves asthma symptoms and should be encouraged. Breathing exercise programmes can be offered to people with asthma as an adjuvant to pharmacological treatment, to improve quality of life and reduce symptoms. Allergen avoidance. There is little evidence that reducing allergen exposure reduces morbidity from asthma and it does not appear to be a cost-effective treatment for asthma. Avoiding house dust mite allergen (bed covers, carpet removal, high-temperature washing of bedding, dehumidification and use of acaricides on soft furnishings) requires commitment beyond what is possible in most households. Similarly, cat and dog allergens are potent triggers for many people's asthma. Again, however, observational evidence that removal of the pet from the household improves asthma control, is lacking. Nonetheless, expert consensus usually advocates their removal. Dietary modifications (use of probiotics, antioxidants, fish oils/lipid supplements, magnesium) and complementary therapies are not currently supported by the guidelines. Drug treatment Step up/down management of chronic asthma: Step 1: mild, intermittent asthma Prescribe an inhaled short-acting beta2 agonist as a short-term reliever for all patients with symptomatic asthma. Good asthma control is associated with little or no need for a short-acting beta2 agonist. Anyone prescribed more than one short-acting bronchodilator inhaler device a month should be identified and have their asthma assessed urgently and measures taken to improve asthma control if this is poor. Regular use of bronchodilators alone may be linked with worsening asthma and asthma deaths. Step 2: introduction of regular preventer therapy Inhaled corticosteroids (ICS) are the most effective preventer drug for adults and older children for achieving overall treatment goals. ICS should be considered for patients with any of the following asthma-related features: Asthma attack in the last two years. Using inhaled beta2 agonists three times a week or more. Symptomatic three times a week or more. Waking one night a week. Titrate the dose of ICS to the lowest dose at which effective control of asthma is maintained. Smokers may require higher preventive doses than non-smokers. ICS are the first-choice preventer drug. There are alternative, less effective preventer therapies for patients taking short-acting beta2 agonists alone: Leukotriene receptor antagonists (LTRAs) have some beneficial clinical effect. Sodium cromoglicate and nedocromil sodium are of some benefit. Theophyllines have some beneficial effect. Antihistamines and ketotifen are ineffective. Step 3: add-on therapy NICE advises that an LTRA such as montelukast should be tried as initial add-on therapy before considering an inhaled long-acting beta2 agonist (LABA). LABAs include salmeterol and formoterol. The addition of an inhaled LABA to ICS alone improves lung function and symptoms and decreases asthma attacks in adults. Inhaled LABAs should not be used without ICS. Review after a trial of therapy - continue if successful in controlling symptoms well. Discontinue after a trial of therapy if no benefit is seen. Then, increase the inhaled steroid dose to 800 micrograms/day beclometasone propionate or equivalent. If control remains suboptimal, consider a trial of another add-on therapy such as modified-release theophylline. If asthma control remains suboptimal after the addition of an inhaled LABA then the dose of ICS should be increased from low dose to medium dose, if not already on this dose. Step 4: poor control on moderate dose of inhaled steroid plus add-on therapy If control remains poor on low-dose ICS plus an LRTA and an LABA, recheck the diagnosis, assess adherence to existing medication and check inhaler technique before increasing therapy. If more intense treatment is appropriate, the following alternatives can be considered. Discuss with the patient whether or not the LRTA should be continued. If there is an improvement when a LABA is added (with or without an LRTA) but control remains inadequate: continue the LABA and increase the dose of ICS, or continue the LABA and the ICS and add tiotropium bromide (a long-acting muscarinic antagonist - LAMA). If there is no improvement when a LABA is added, stop the LABA and try: an increased dose of ICS, or LAMA (LAMAs are not licensed for this indication). Other approaches Theophyllines may improve lung function and symptoms; however, side-effects occur more often. Slow-release beta2-agonist tablets may also improve lung function and symptoms but side effects occur more often. The addition of short-acting anticholinergics is generally of no value. The addition of nedocromil is of marginal benefit. If control remains inadequate after stopping a LABA and increasing the dose of ICS, consider sequential trials of add-on therapy, ie theophyllines, or slow-release beta2-agonist tablets (in adults only). If control remains inadequate on medium dose of an ICS plus a LABA, the following interventions can be considered: Increase the ICS to high dose (adults) or Consider changing to an inhaler which delivers a combination of ICS and a fast-acting LABA. This is called maintenance and reliever therapy (MART). Add a theophylline; or Add slow-release beta2-agonist tablets, although caution needs to be used in patients already on LABAs; or Add tiotropium (adults). At high doses of ICS via a pressurised metered-dose inhaler (pMDI), a spacer device should be used. Step 5: continuous or frequent use of oral steroids For the small number of patients not controlled on high-dose therapies, use daily steroid tablets in the lowest dose providing adequate control. These patients should always be under the care of a respiratory physician. Patients on long-term steroid tablets (longer than three months) or requiring frequent courses of steroid tablets (three to four per year) will be at risk of systemic side-effects: Blood pressure should be monitored. Urine or blood sugar and cholesterol should be checked: diabetes mellitus and hyperlipidaemia may occur. Bone mineral density should be monitored in adults. When a significant reduction occurs, treatment with a long-acting bisphosphonate should be offered. Cataracts and glaucoma may be screened for through community optometric services. Stepping down Review treatment every three months. Step it down if possible (but consider seasonal variation in symptoms, severity of asthma, risk of adverse effects, patient preference) and use the lowest possible dose of ICS to control the asthma symptoms. When reducing inhaled steroids, cut the dose slowly by 25-50% each time. Combination products Increasingly, combination inhalers of LABAs and low-dose inhaled steroids (eg, Symbicort® = formoterol and budesonide, Seretide® = salmeterol and fluticasone) are being marketed and used. These products are convenient since many patients are on a maintenance dose of both types of drugs and should be expected to improve adherence. However, they should only be used if the patient requires both drugs and has previously been stabilised on a dosage regimen that is deliverable by the combination inhaler. Using combined inhalers makes it harder to assess whether a patient still requires both drugs and in what doses and so the LABA or ICS may not be stepped down appropriately. Biologic treatments - monoclonal antibodies There are currently five biological treatments approved for use in the UK and available on the NHS to treat severe asthma. All can be started by specialists under certain criteria. All are injections, apart from reslizumab which is delivered via intravenous infusion. These are: Omalizumab (Xolair®). Mepolizumab (Nucala®). Reslizumab (Cinqaero®). Benralizumab (Fasenra®). Dupilumab (Dupixent®). Omalizumab NICE recommends omalizumab as an option for treating severe persistent confirmed allergic IgE-mediated asthma as an add-on to optimised standard therapy in people aged 6 years and older who need continuous or frequent treatment with oral corticosteroids (defined as four or more courses in the previous year). Omalizumab should only be initiated by a specialist. Optimised standard therapy is defined as a full trial of and, if tolerated, documented compliance with high-dose ICS, LABAs, LRTAs, theophyllines, oral corticosteroids, and smoking cessation if clinically appropriate. Mepolizumab[60599 : NICE TA671 Mepolizumab for treating severe eosinophilic asthma remove] NICE has issued recommendations on the use of mepolizumab in patients with severe eosinophilic asthma. It is only recommended as an add-on therapy to patients with severe refractory asthma not controlled with an optimised standard treatment plan. It is given as an injection every four weeks. Mepolizumab may be suitable for age 6 years and above. Only children aged 12 years or above can be given treatments to use at home. In addition, they must fulfil the following criteria: Blood eosinophil count has been recorded as at least 300 cells/mcl or more and they have had at least four exacerbations needing systemic corticosteroids in the previous year, or had continuous oral corticosteroids of at least the equivalent of prednisolone 5 mg per day over the previous six months; or Blood eosinophil count has been recorded as at least 400 cells/mcl and they have had at least three exacerbations needing systemic corticosteroids in the previous year. Reslisumab[60601 : NICE TA479 Reslizumab for treating severe eosinophilic asthma remove] Reslizumab is suitable for adults aged 18 and over. It is given as an intravenous infusion every four weeks. Patients must fulfil the following criteria: Eosinophil count has reached 400 cells or more and they have had at least three or more asthma attacks needing steroid tablets or injections in the past 12 months. Patient is based in England, Wales or Northern Ireland. It's not available in Scotland yet. Benralizumab[60600 : NICE TA565 Benralizumab for treating severe eosinophilic asthma remove] Benralizumab is suitable for adults aged 18 and over. It is given as an injection every four weeks for the first three doses, then eight-weekly thereafter. Patients must fulfil the following criteria: Eosinophil count has reached 300 cells or more; and Had four or more asthma attacks needing steroid tablets or injections in the past 12 months; or Had continuous steroids of at least 5 mg prednisolone per day over the previous six months. If the patient has responded well to benralizumab after 12 months, they can continue on it with a yearly review. Dupilumab Dupilumab as an option for add-on maintenance therapy in severe asthma with type 2 inflammation that is inadequately controlled in people aged 12 years and over, despite maintenance therapy with high-dose inhaled corticosteroids and another maintenance treatment, if: The dosage used is 400 mg initially and then 200 mg subcutaneously every other week. The person has agreed to and follows an optimised standard treatment plan. The person has a blood eosinophil count of at least 150 cells/mcl and FeNO of at least 25 parts/billion, and has had at least four or more exacerbations in the previous 12 months. The person is not eligible for mepolizumab, reslizumab or benralizumab, or has asthma that has not responded adequately to these biological therapies. Editor's note Dr Krishna Vakharia, 21st April 2023 Tezepelumab for treating severe asthma NICE has recommended tezepelumab as an add-on to maintenance treatment in people 12 years and over with severe asthma, when treatment with high-dose inhaled corticosteroids plus another maintenance treatment has not worked well enough to treat severe asthma. Studies have shown that when this medication is given alongside usual asthma medication, it reduces exacerbations and the dose of oral corticosteroids needed. Criteria for prescribing by specialists are: The person has had three or more exacerbations in the previous year. The person is taking maintenance oral corticosteroids. In addition, tezepelumab should be stopped if the rate of severe asthma exacerbations, or the maintenance oral corticosteroid dose, has not been reduced by at least 50% at 12 months. Management of acute asthma See the separate Acute Severe Asthma and Status Asthmaticus article - treat as an emergency. Current evidence does not support increasing the dose of ICS as part of a self-initiated action plan to treat exacerbations in patients with mild-to-moderate asthma. Increased ICS dose is not associated with a statistically significant reduction in the odds of requiring rescue oral corticosteroids for the exacerbation, or of having adverse events, compared with a stable ICS dose. Asthma in pregnancy Asthma's course in pregnancy is very variable. The risk of deterioration is highest in those with severe asthma but, equally approximately, a third of women with asthma improve symptomatically during pregnancy. Up to a fifth of pregnant women with asthma require emergency treatment, of which two thirds require hospitalisation. Well-controlled asthma minimises the risk of fetal and maternal complications. Pre-pregnancy, optimise control and emphasise the importance of continuing medication in pregnancy. Closely monitor pregnant women with asthma, so that appropriate changes to their treatment can be quickly implemented in response to changed symptoms. Treat exacerbations vigorously, in particular ensuring oxygen saturation is maintained above 95%. In general, asthma medications are believed to be safe in pregnancy - women should be reassured regarding treatments. Inhaled short- and long-acting beta2 antagonists, ICS and oral and intravenous theophyllines can be used as normal during pregnancy. Acute severe asthma in pregnancy is an emergency and should be treated vigorously in hospital. Smoking cessation and breastfeeding should be particularly encouraged in women with asthma. Asthma drugs can be used as normal in breastfeeding women. Inhaler and spacer devices See also the separate Which Device in Asthma? and Nebulisers in General Practice articles. Asthma management can be confusing given the array of devices, masks and spacers used to deliver inhaled drugs. When considering which inhaler device, consider manual dexterity and other necessary abilities to activate a particular device, factors such as portability and convenience and the patient's willingness to use a particular device. Whenever an inhaler is prescribed, training should be given and technique checked regularly to ensure that it is being used correctly. The first-line choice for delivery of ICS and bronchodilators in the treatment of stable asthma is the pMDI +/- a spacer device. Other alternative inhaler devices have not been shown to be more effective than pMDI and are more expensive. They are also considered first-line for the delivery of treatment for mild-to-moderate asthma exacerbations and are at least as effective as a nebuliser in these situations. Large-volume spacer devices are useful for increasing drug delivery to the lungs and may be used for all patients but are strongly indicated for those who have difficulty co-ordinating pMDI activation with inhalation and those on high doses of ICS (>800 micrograms/day). Portability of spacers can be an issue. In the very young, a face mask should be used with the pMDI and spacer combination, until the spacer mouthpiece can be reliably used. If this is ineffective, a nebuliser should be considered. pMDIs vary in their global-warming potential, and where a number of devices are equally effective and acceptable to patients, prescribers are advised to select the one with the least environmental impact. Patients should be advised to ask a pharmacist whether their device is recyclable. Referral The decision to refer is influenced by local referral pathways, the individual and the experience of the primary healthcare provider. In addition to respiratory physicians and paediatricians with a specialised interest in respiratory medicine, other specialists such as dieticians, physiotherapists, occupational therapists and respiratory nurse specialists may be involved in the management of asthma. Admit or refer adults for specialist assessment or further investigation in the following situations: Severe acute asthma. The diagnosis is unclear or in doubt: Unexpected clinical findings (for example, crackles, clubbing, cyanosis, cardiac disease). Persistent non-variable breathlessness. Monophonic, unilateral or fixed wheeze or stridor. Persistent chest pain or atypical features. Prominent systemic features (for example, weight loss, myalgia, fever). Persistent cough or sputum production. Spirometric or PEFR measurements that do not fit the clinical picture (for example, unexplained restrictive spirometry). Suspected occupational asthma. Non-resolving pneumonia. Inadequate response to maximum guideline treatment.

13 Jun 2022

service upsell

Sign up to FourteenFish

FourteenFish provide an appraisal toolkit as well as a host of learning tools to make the recording of learning easy for healthcare professionals.

Professional Articles A-Z